Eli Lilly is planning to introduce an oral version of its experimental weight-loss drug, aiming to expand its presence in India’s fast-growing obesity care market following the launch of its injectable therapy earlier this year.

The US-based pharmaceutical company is preparing regulatory submissions for its once-daily pill, or forglipron, designed for chronic weight management. The company expects to file in India by the end of this year, with approvals anticipated by the second half of 2026. Submissions for type 2 diabetes indications will follow in early 2026, with possible approvals by late 2026 or early 2027.

India, where the anti-obesity drug market is valued at approximately ₹752 crore, is a priority geography for Lilly’s global rollout. The company’s leadership underscored that India would be part of the first wave of submissions, reflecting the strategic importance of oral therapies in markets where patient preference leans heavily toward pills. More than 75 per cent of patients in India opt for oral formulations when comparable efficacy is available.

Patrik Jonsson, executive vice president of Eli Lilly and president of Lilly International, said the new drug would complement Mounjaro (tirzepatide), the injectable launched in India in March 2025. While injectables typically serve patients with higher body mass index (BMI) thresholds - often above 35 - orforglipron is positioned for patients in the 27–34 BMI range, a segment representing the majority of India’s obesity burden.

Global clinical data underpins the company’s confidence. In a head-to-head Phase 3 trial (ACHIEVE-3), orforglipron outperformed Novo Nordisk’s oral semaglutide (Rybelsus) in both weight reduction and glycemic control. Results showed a mean HbA1c reduction of up to 2.2 per cent versus 1.4 per cent with semaglutide. Weight loss was also significantly higher: 8.9 kilograms (9.2 per cent) at the highest dose compared with 5.0 kilograms (5.3 per cent). The study enrolled more than 4,500 patients worldwide, including participants from India, strengthening the drug’s relevance to local populations.

Unlike injectable GLP-1 therapies, orforglipron is a small-molecule drug that does not require cold-chain logistics. This distinction has important implications for India, where temperature-controlled supply chains remain uneven. Eliminating the need for refrigeration could widen distribution to smaller towns and semi-urban areas, addressing gaps in access that persist despite rising demand.

Pricing is expected to be another differentiator. Jonsson indicated that Lilly will adopt a “value-based pricing” model for orforglipron in India, weighing the drug’s clinical benefits against the country’s healthcare needs and existing therapies. While no specific figures were disclosed, Lilly suggested that oral formulations would be easier to produce at scale and therefore more cost-effective than peptide-based injectables. This approach could broaden adoption beyond urban, high-income groups to a larger patient base.

The launch comes at a time when India is grappling with rising rates of obesity and associated conditions such as diabetes and cardiovascular disease. Estimates suggest that more than 100 million Indians are living with obesity or are overweight, with urban prevalence rising sharply in the last decade. While lifestyle modification remains the cornerstone of obesity management, demand for pharmacological solutions has expanded rapidly, mirroring global trends.

For India’s healthcare ecosystem, the entry of an oral weight-loss drug raises several questions. Hospitals and clinicians will need to integrate obesity pharmacotherapy alongside existing surgical and behavioral interventions. Payers and insurers, who have historically limited coverage for anti-obesity drugs, may also need to reassess their frameworks if wider adoption is to be achieved. For investors and pharmaceutical peers, Lilly’s move signals intensifying competition in a market segment that is both medically urgent and commercially significant.

Jonsson highlighted the scalability advantage of oral therapies in this context: “With injectables we rely on cold chains, and that is something we are eliminating here. You can reach patients across the globe at a scale that is not possible today.”

If approved on schedule, orforglipron could mark a pivotal shift in how obesity is treated in India, opening the market to millions who prefer oral medications while reducing logistical barriers for manufacturers and distributors. Combined with the injectable GLP-1 class, India’s therapeutic arsenal against obesity would be significantly expanded, with potential downstream benefits in reducing the burden of diabetes and cardiovascular disease.

As obesity becomes a central public health challenge, Eli Lilly’s strategy reflects both the evolving preferences of Indian patients and the broader structural needs of its healthcare system. The company’s dual-track approach - injectables for severe cases and oral drugs for a wider patient pool - could reshape obesity management and set the stage for more accessible, scalable interventions in the coming decade.